Krilogy Financial LLC Acquires New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Krilogy Financial LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,822 shares of the biopharmaceutical company’s stock, valued at approximately $1,661,000.

A number of other institutional investors have also recently added to or reduced their stakes in ALNY. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $243,000. Geneos Wealth Management Inc. grew its holdings in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 175 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in Alnylam Pharmaceuticals by 47.3% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,390 shares of the biopharmaceutical company’s stock worth $4,368,000 after acquiring an additional 4,302 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 15.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,917 shares of the biopharmaceutical company’s stock valued at $1,277,000 after acquiring an additional 522 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its holdings in Alnylam Pharmaceuticals by 34.3% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 1,164 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 297 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Down 0.3%

NASDAQ:ALNY opened at $321.99 on Thursday. The firm has a market capitalization of $42.54 billion, a price-to-earnings ratio of 1,341.60 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. The business’s fifty day moving average price is $380.99 and its 200 day moving average price is $424.91.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,780 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the sale, the executive vice president directly owned 29,728 shares of the company’s stock, valued at $10,787,399.36. This trade represents a 4.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 31,305 shares of company stock valued at $12,459,785 over the last ninety days. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Truist Financial cut their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Jefferies Financial Group dropped their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Bank of America reduced their price objective on Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 target price (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, Needham & Company LLC increased their price target on Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $477.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.